With a whopping hike of 98% in 2Q2015 ingredient sale, Chromadex Corp (OTCMKTS:CDXC) has continued its excellent growth oriented performance the fifth time in a row. It’s better known for health, nutritional and wellness ingredients that are used for various requirements related to skincare, food & beverage, pharmaceutical products and sports nutrition.
Insights On The Matter:
Chromadex generated total sales of $6.1 million during the three-month period ending July 4, 2015, as compared to $3.9 million during the same period in 2014. Overall sales of Chromadex increased 58% on YOY basis and 16% on a Q-o-Q basis. It’s because of more than expected sales in company’s ingredient business led by NIAGEN branded nicotinamide riboside that helped the company touching such great figure. The ingredient business alone accounted for net sales of $3.4 million in 2Q2015, 98% more than last year’s performance and 27% more than 1Q2015’s performance.
Apart from this, the core standard & service department of the company also posted a whopping $2.4 million sale in the July quarter. It was 28% more than what Chromadex had generated a year ago. The scientific and regulatory consulting department of Chromadex was able to generate sales worth $318K in 2Q2015, 15% higher than the last year.
Despite this extraordinary performance, its loss for common stockholders in 2Q2015 was $0.00 per share or $315K in total against last year’s $0.02 per share or $1.7 million in total.
The senior management of the company is delighted to perform this well. According to Frank Jaksch, Jr., Co-Founder & CEO, Chromadex Corp (OTCMKTS:CDXC), it’s the fifth consecutive time when Chromadex has been able to post record revenues. This performance shows how well the company is moving towards concluding an overall excellent year. New companies are taking an interest in company’s NIAGEN nicotinamide riboside.
Chromadex has indulged in talks with three Fortune 500 companies to figure out any possibility of its ingredients being featured in a wide range of branded consumer products. It will keep updating about future growth from time to time.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: